- Home
- ANL vs LPTX Comparison
ANL vs LPTX Comparison
Compare ANL & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- LPTX
- Stock Information
- Founded
- ANL 2004
- LPTX 2011
- Country
- ANL Cayman Islands
- LPTX United States
- Employees
- ANL N/A
- LPTX N/A
- Industry
- ANL
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANL
- LPTX Health Care
- Exchange
- ANL Nasdaq
- LPTX Nasdaq
- Market Cap
- ANL 84.5M
- LPTX 99.5M
- IPO Year
- ANL 2023
- LPTX N/A
- Fundamental
- Price
- ANL $2.14
- LPTX $3.11
- Analyst Decision
- ANL Strong Buy
- LPTX Strong Buy
- Analyst Count
- ANL 2
- LPTX 3
- Target Price
- ANL $9.00
- LPTX $7.50
- AVG Volume (30 Days)
- ANL 9.6K
- LPTX 437.3K
- Earning Date
- ANL 08-08-2024
- LPTX 11-13-2024
- Dividend Yield
- ANL N/A
- LPTX N/A
- EPS Growth
- ANL N/A
- LPTX N/A
- EPS
- ANL N/A
- LPTX N/A
- Revenue
- ANL $5,000,000.00
- LPTX N/A
- Revenue This Year
- ANL N/A
- LPTX N/A
- Revenue Next Year
- ANL N/A
- LPTX N/A
- P/E Ratio
- ANL N/A
- LPTX N/A
- Revenue Growth
- ANL N/A
- LPTX N/A
- 52 Week Low
- ANL $1.85
- LPTX $1.68
- 52 Week High
- ANL $17.48
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- ANL 43.45
- LPTX 51.79
- Support Level
- ANL $2.23
- LPTX $2.87
- Resistance Level
- ANL $2.44
- LPTX $3.12
- Average True Range (ATR)
- ANL 0.19
- LPTX 0.28
- MACD
- ANL -0.01
- LPTX 0.02
- Stochastic Oscillator
- ANL 23.43
- LPTX 49.42
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .